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AbstrAct
Introduction Despite widespread availability of clinical 
practice guidelines (CPGs), considerable gaps continue 
between the care that is recommended (‘appropriate 
care’) and the care provided. Problems with current CPGs 
are commonly cited as barriers to providing 'appropriate 
care'. Our study aims to develop and test an alternative 
method to keep CPGs accessible and up to date. This 
method aims to mitigate existing problems by using a 
single process to develop clinical standards (embodied 
in clinical indicators) collaboratively with researchers, 
healthcare professionals, patients and consumers. 
A transparent and inclusive online curated (purpose-
designed, custom-built, wiki-type) system will use an 
ongoing and iterative documentation process to facilitate 
synthesis of up-to-date information and make available 
its provenance. All participants are required to declare 
conflicts of interest. This protocol describes three phases: 
engagement of relevant stakeholders; design of a process 
to develop clinical standards (embodied in indicators) for 
‘appropriate care’ for common medical conditions; and 
evaluation of our processes, products and feasibility.
Methods and analysis A modified e-Delphi process will 
be used to gain consensus on ‘appropriate care’ for a 
range of common medical conditions. Clinical standards 
and indicators will be developed through searches of 
national and international guidelines, and formulated 
with explicit criteria for inclusion, exclusion, time frame 
and setting. Healthcare professionals and consumers 
will review the indicators via the wiki-based modified 
e-Delphi process. Reviewers will declare conflicts of 
interest which will be recorded and managed according to 
an established protocol. The provenance of all indicators 
and suggestions included or excluded will be logged 
from indicator inception to finalisation. A mixed-methods 
formative evaluation of our research methodology will be 
undertaken.
Ethics and dissemination Human Research Ethics 
Committee approval has been received from the University 
of South Australia. We will submit the results of the study 
to relevant journals and offer national and international 
presentations.
IntroductIon
In Australia, ‘appropriate care’ (care in line 
with evidence or consensus-based guidelines) 
is provided to adults, on average, only 57% of 
the time, with large variations across common 
medical conditions and providers.1 Problems 
with clinical practice guidelines (CPGs), 
standards and indicators (see box 1 for defi-
nitions) are commonly cited as one of the 
barriers to providing appropriate care2; these 
include large numbers of repositories and 
guidelines; duplication and overlap among 
guidelines; differing recommendations for 
care practices; lack of currency; inconsistent 
structure and content; voluminous docu-
ments which are not easy to assimilate or 
use3–5; and recommendations which are often 
vague and difficult to measure.2 6 7 In addi-
tion, most CPGs lack detail of how evidence 
was interpreted and weighted to formulate 
recommendations, offer little opportunity for 
end-users to provide formal feedback8 and 
have been developed by people with (often 
undisclosed) professional or commercial 
conflicts of interest (COIs).2 6 9
Implementability of CPGs is a key 
factor affecting their perceived utility and 
uptake11 15; in response, international efforts 
are being directed at developing clinical 
STANDING Collaboration: a study 
protocol for developing 
clinical standards
Louise K Wiles,1,2 Peter D Hibbert,1,2,3,4,5 Jacqueline H Stephens,1 Enrico Coiera,5 
Johanna Westbrook,3 Jeffrey Braithwaite,2 Ric O Day,6 Ken M Hillman,7,8 
William B Runciman1,4
To cite: Wiles LK, Hibbert PD, 
Stephens JH, et al.  STANDING 
Collaboration: a study 
protocol for developing 
clinical standards. BMJ Open 
2017;7:e014048. doi:10.1136/
bmjopen-2016-014048
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files please visit the 
journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2016- 
014048).
Received 26 August 2016
Revised 29 May 2017
Accepted 12 June 2017
For numbered affiliations see 
end of article.
correspondence to
Professor William B Runciman;  
 william. runciman@ unisa. edu. au
Protocol
strengths and limitations of this study
 ► We will develop and evaluate a method for 
generating and ratifying clinical standards and 
indicators of ‘appropriate care’ for common health 
conditions which has been designed to overcome 
deficiencies in current methods.
 ► This study will obtain expert consensus on 
‘appropriate care,’ underpinned by evidence, for a 
range of common medical conditions.
 ► The recruitment of healthcare professionals, 
patients and consumers to review clinical indicators 
may introduce selection biases.
 ► The use of English language clinical practice 
guidelines may not be representative of all available 
evidence, and limits the generalisability of study 
findings.
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box 1 definitions for clinical practice guideline, standard, 
indicator and tool.
A clinical practice guideline:
‘Statements that include recommendations intended to optimize 
patient care that are informed by a systematic review of evidence 
and an assessment of the benefits and harms of alternative care 
options.10 11
A clinical standard2:
 ► is an agreed process that should be undertaken or an outcome that 
should be achieved for a particular circumstance, symptom, sign or 
diagnosis (or a defined combination of these)
 ► should be evidence based, specific, feasible to apply, easy and 
unambiguous to measure, and produce a clinical benefit and/or 
improve the safety and/or quality of care, at least at the population 
level.
If a standard cannot or should not be complied with, the reason/s 
should be briefly stated.
 A clinical indicator2:
 ► describes a measurable component of the standard, with explicit 
criteria for inclusion, exclusion, time frame and setting.
A clinical tool2 6 12–14:
 ► should implicitly or explicitly incorporate a standard or a component 
of a standard
 ► should constitute a guide to care that facilitates compliance with 
the standard
 ► should be easy to audit, preferably electronically, to provide feedback
 ► should be able to be incorporated into workflows and medical 
records.
standards and indicators to identify evidence and service 
delivery gaps and areas for improvement, and understand 
and measure the quality of care provided.16 17 Emerging 
schools of thought suggest that ‘appropriate care’ may 
be enhanced through greater patient (health consumer) 
engagement.12–14 18 This could be facilitated by involving 
patients and interested laypeople as well as healthcare 
professionals (HCPs) in CPG development,6 19 20 and 
using online technologies to enhance transparency, 
accessibility and currency of both content and develop-
ment processes.6 21
The strategies employed in this protocol aim to miti-
gate problems with existing CPG development processes 
(table 1) by adopting a single approach to avoid dupli-
cation, using an ongoing and iterative documentation 
process to facilitate transparent synthesis of up-to-date 
information and make its provenance accessible, and 
requiring all participants to declare their COIs.2 Indica-
tors will be developed using selection criteria to reflect 
‘essential’ clinical practice and be expressed one concept 
at a time in plain English to help create standards that are 
clear, concise, measurable and easy to use.
The aims of the STANDING Collaboration study are to 
(1) provide proof of concept for an alternative method 
for creating sets of nationally-agreed evidence-based stan-
dards and clinical indicators, and (2) obtain consensus 
on ‘appropriate care’ for a range of common medical 
conditions. To do so, we will use a three-phase approach to 
engage relevant stakeholders, develop clinical indicators 
representative of ‘appropriate care’ (which constitute the 
standard) for a range of common conditions, and eval-
uate our processes, products and feasibility. We plan to 
develop an inclusive, transparent, collaborative process, 
which allows HCPs and patients or consumers to develop 
and keep up-to-date clinical standards comprising indica-
tors with defined attributes, using an online curated wiki-
based platform to facilitate ongoing review and updating 
of the standard, or individual indicators, as soon as new 
evidence emerges. In this study, the term ‘wiki’ refers to 
an interactive information management system which 
will allow users (eg, HCPs and patients) to collaborate 
directly in formulating and refining indicators that are 
relevant to their clinical practice and lived experience.21 22 
The source and provenance of each indicator, including 
all suggestions, will be posted online and updated as 
necessary.
MEthods And AnAlysIs
Our three-phase approach (figure 1) comprises:
1. stakeholder analysis;
2. development and test of a process for creating clinical 
indicators representative of ‘appropriate care’ for a 
range of common conditions;
3. evaluation of processes, products and feasibility.
PhAsE 1
In order to gain an understanding of potential barriers, 
facilitators and the overall feasibility of the STANDING 
Collaboration methodology, stakeholder perspectives will 
be captured through a series of semistructured qualitative 
telephone interviews. HCPs and consumers will be invited 
to participate. Relevant medical colleges, professional and 
consumer associations and networks will be contacted, 
using publicly available information, to request assistance 
with the recruitment of interview participants. Invitations 
will comprise email notifications to members and media 
releases and articles within newsletters, asking potential 
participants to contact the Research Team members. The 
telephone interviews will be conducted at a time conve-
nient to the research team member and the participant. 
Based on the sample sizes reported in similar stakeholder 
analyses,23 24 we anticipate conducting approximately 
18–25 interviews in total (9–13 interview participants per 
stakeholder type), or until saturation is reached.
Using guidelines for stakeholder analyses25 and 
the schedules from previous qualitative research as a 
guide,19 24 a range of topics will be explored in the inter-
views (table 2).
Interviews will be recorded with consent and tran-
scribed by a professional transcription company. Tran-
scripts and summaries will be returned to participants 
for the purpose of making comments or corrections and 
providing feedback on the findings.26 Content analyses 
 on 16 S
eptem









pen: first published as 10.1136/bm





 3Wiles LK, et al. BMJ Open 2017;7:e014048. doi:10.1136/bmjopen-2016-014048
Open Access
Table 1 Key aspects of the STANDING Collaboration methodology, designed to mitigate issues with current CPG 
development
CPG development issue STANDING Collaboration methodology and rationale
Large numbers of repositories 
and guidelines2 6
Single approach negates the need for, and replaces aggregated findings from, a large 
number of repositories and guidelines
Duplication and overlap2
Different recommendations for 
care practices2 6
Methodology will produce a single set of nationally agreed evidence-based clinical 
indicators, representative of ‘appropriate care’ for a range of common medical conditions, 
reflecting consensus recommendations for care practices
Lack of currency2 6 Methodological vehicle (interactive, live and online wiki-based platform) will facilitate ongoing 
review and ease of updating
Inconsistent structure and 
content2
Uniform methodological approach and format will ensure consistent structure and content
Hard-to-use voluminous 
documents2
Methodological vehicle (live and online wiki-based platform) and consistent organisation of 
indicators according to phases of care will facilitate ease of access and use
Hard-to-measure 
recommendations2
Uniform methodological approach will ensure consistent structure and content for indicators, 
which will be formatted to ensure ‘measurable components of the standard, with explicit 
criteria for inclusion, exclusion, time frame and setting’2
Management of conflicts of 
interest2 6 9 36 49
Research methodology requires participants to declare any conflicts of interest, and has a 
defined management strategy for these
The source and provenance of each standard, indicator and suggestion will be logged and 
can be viewed
Inclusive, catering for all target 
audiences19 23
This method allows for all healthcare professional types and patients
or consumers to register and review indicators
Lacking details on how evidence 
was sourced, interpreted 
and managed to formulate 
recommendations8
All reviewers’ comments and recommendations will be logged, classified and presented in 
subsequent rounds according to whether and why they have been incorporated into the next 
iteration
This allows tracking of the evolution of the standards and indicators from the original 
recommendations on which they were based to their final iteration, as well as the nature and 
influence of review feedback in shaping the standard
CPG, clinical practice guideline.
will be used to derive common themes. We will use open 
coding and inductive reasoning with two coders to 
group similar responses into categories and assign labels 
capturing specific themes. Any discrepancies will be 
discussed among Research Team members. After agree-
ment is reached on the composition and label for each 
category, we will assign (axial coding) categories to the 
central phenomena of interest (table 2).27 28
PhAsE 2
Clinical indicators will be developed for individual condi-
tions using a four-stage process:
I. source, select and search relevant CPGs;
II. extract all concepts from each CPG together with the 
relevant text in which they appear (original recom-
mendation), and tabulate common concepts to se-
lect, draft and format the proposed clinical indicators 
based on identified concepts;
III. review the indicators internally;
IV. review the indicators externally.
stage I: source, select and search relevant cPGs
Interview data from the stakeholder analysis (phase 1) will 
be used in conjunction with national health priority areas, 
burden of disease and prevalence data to identify candi-
date conditions for clinical standard and indicator devel-
opment.1 7 Clinical indicators will be drawn initially from 
the latest CPGs. A systematic search will be undertaken of 
national-level Australian CPGs endorsed by the National 
Health and Medical Research Council, and internation-
al-level guidelines from the National Institute for Health 
and Care Excellence in England, Scottish Intercollegiate 
Guidelines Network, and the Agency for Healthcare 
Research and Quality's National Guideline Clearinghouse 
in the USA, and the Guidelines International Network. In 
the absence of Australian national or international CPGs, 
relevant professional medical college and association CPGs 
may also be searched, as well as those published at state 
or professional level and in international journals. Details 
of the search strategy are provided in appendix A, online 
supplementary file 1.29 30 In order to describe the quality of 
the evidence sources from which our clinical indicators will 
be derived, two members of the Research Team will inde-
pendently appraise CPGs using the AGREE-II (Appraisal of 
Guidelines for Research and Evaluation II) tool.31–34
stage II: select, draft and format proposed indicators
Recommendations (and their key underlying concepts) 
from each CPG will be collated and used to inform the 
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Figure 1 Overview of STANDING Collaboration research methodology and definitions for participant groups. CPG, clinical 
practice guideline.
Table 2 Topics (and their rationale) for exploration in the qualitative stakeholder interviews
Interview topic Rationale
Strength and limitations of current CPGs, clinical standards 
and indicators (eg, in terms of development, availability and 
utility)
Background information regarding participants’ understanding 
of the development, availability and utility of CPGs
Barriers, facilitators and the overall feasibility of the STANDING 
Collaboration methodology
To refine the STANDING Collaboration methodology according 
to stakeholders’ needs
Possible integration of standards into patient decision support 
technologies and what these would comprise
To tailor the content and format of clinical standards and 
indicators to optimise fitness for purpose
Priorities for standard development topics (ie, medical 
conditions)
To determine methods and data sources for selecting priority 
medical conditions for indicator development in the STANDING 
Collaboration study
CPG, clinical practice guideline.
content of the proposed clinical indicators. Not all recom-
mendations published in CPGs will become indicators. 
Recommendations will be flagged for potential exclusion 
based on the following criteria:
 ► strength of the wording of the recommendation 
(ie, 'may' and 'could' statements would be excluded; 
'should' and 'must' statements would be included)
 ► vague guiding or aspirational statements and those 
without recommended actions
 ► conflicting recommendations from less recent CPGs 
and those with lower AGREE-II scores.
All clinical indicators will be written in plain English, 
one concept at a time, using a structured and standard-
ised format (eg, commencing with the inclusion criteria 
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followed by the compliance action)7 (table 3). For each 
condition, indicators will be arranged according to phases 
of care (ie, screening, diagnosis, assessment, acute care, 
ongoing care) so that together, they constitute a clinical 
standard amendable to inclusion as a clinical tool over 
the patient journey.
stages III and IV: iterative review using a modified e-delphi 
approach
Stages III and IV will involve online wiki-based reviews 
of proposed clinical indicators; initially by way of an 
internal review between the Research Team and Curator 
Group (stage III), followed by an external review by the 
Curator Group and HCPs and consumers who choose to 
register to the site (Wiki Registrants) and provide feed-
back on the proposed clinical indicators.7 This approach 
has been chosen to facilitate the number and spread of 
individuals’ perspectives obtained and avoid domination 
of the consensus process by one or a few participants, 
and to optimise face validity of the final set of clinical 
standards and indicators.7 35 All STANDING Collabora-
tion participants (Research Team, Clinical Champion, 
Curator Group members, and Wiki Registrants) will be 
required to complete a COI declaration, which will be 
taken into consideration when accepting or rejecting 
suggestions, and logged with the provenance of each indi-
cator for transparency.9 36
stage III: internal review processes
Internal reviews will first be conducted within our 
Research Team, and subsequently by our Clinical Cham-
pion and Curator Group members who will comprise a 
mix of at least two members of the following: clinicians 
(eg, general practitioners, medical specialists, allied 
health professionals, nurses), researchers, policymakers 
or public health specialists or healthcare quality improve-
ment experts, and consumers. Depending on their 
self-reported scope of practice, expertise and interest, 
Curator Group members (including consumers) may be 
able to participate in review panels for more than one 
condition. The total number of invitations to potential 
Curator Group members will depend on the skill mix of 
those invited and the overall pattern of recruitment. This 
selection strategy is supported within the Delphi process 
literature with studies using similar criteria to choose 
potential participants (eg, renown, member of an organi-
sation, recommendation, years of experience, willingness 
to participate, availability, interest).7 35
The internal review will consist of a maximum of three 
rounds to allow sufficient testing of the subsequent phase 
of the process (ie, external review). In the first round, 
drafts of proposed clinical indicators, and the recommen-
dations on which they are based, will be sent via email 
to the Curator Group members. The review criteria to 
be used are based on the methods from previous studies 
for developing and measuring indicators of appropriate 
care.1 7 16 37–39 Curator Group members will be asked to: 
recommend indicators for inclusion (with or without 
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amendments) or exclusion, provide comments in relation 
to three key criteria: evidence, feasibility and importance 
(appendix B, online supplementary file 2) and make addi-
tional suggestions (with supporting material). In addition, 
Research Team members will pose specific questions to 
the Curator Group members about individual indicators 
to highlight inconclusive or conflicting CPG recommen-
dations, or to clarify definitions for inclusion criteria and 
compliance actions. In particular, consumer members of 
the Curator Group will be asked to vet the plain English 
wording of clinical indicators and a linked glossary of 
terms to ensure that content is appropriately targeted to 
the consumer audience. In this round, Curator Group 
members will complete their assignments independently 
to minimise ‘group-think.’40 41 Research Team members 
(WBR, PDH, LKW, JHS) will collate the feedback and 
revise the content, structure and format of each indicator. 
The refined set of indicators (including the original indi-
cators and any feedback and suggestions) will be sent to 
the same Curator Group members for a second round of 
scoring. The same approach will be used in the second 
round, with a request for further refinement and identifi-
cation of indicators to be included or excluded. If neces-
sary, Curator Group members will discuss the proposed 
set of indicators via a third round teleconference, with a 
view to achieving consensus and approving the indicators 
for the external online wiki-based review process.
stage IV: external review processes
External reviews will be conducted by HCPs and 
consumers who have registered to this wiki as reviewers 
(Wiki Registrants). Relevant medical colleges, profes-
sional and consumer associations and networks will be 
contacted to request assistance with the identification of 
potential clinical indicator reviewers. Invitations will be 
by email, media releases and articles within newsletters. 
HCPs and consumers will self-nominate as reviewers for 
one or more of the STANDING Collaboration conditions 
based on their interests, scope of practice and experi-
ence.35 42 Wiki Registrants for this process will be required 
to declare their COIs, which will be taken into account by 
the Clinical Champion and Curator Group when consid-
ering reviewers’ feedback on the indicators.9 36
The external review will involve an interactive wiki-based 
process where indicators for each condition from round 
3 of the internal review will be posted on an online wiki 
site. A software development company will be engaged to 
purpose design and custom build the wiki for this project. 
The wiki ‘live’ time for each version will depend on the 
recruitment rate of reviewers and the progress of their 
reviews, but is anticipated to be no longer than 3 months 
per round. Reviewers will provide comments on indicators 
in relation to the three key criteria: evidence, feasibility 
and importance (appendix B, online supplementary file 
2), make recommendations (ie, inclusion, inclusion with 
amendments, exclusion, hold) and be able to suggest edits 
in real time. The Clinical Champion and Curator Group 
for each condition will follow-up and manage external 
reviewers’ responses, and make final recommendations 
for that version regarding the inclusion, content, struc-
ture and format of indicators. The Clinical Champion 
and Curator Group will use supporting references when 
considering and responding to each suggestion related 
to whether and why they have been included or rejected. 
In addition, all external reviewers’ comments and recom-
mendations will be logged, classified and presented in 
subsequent rounds according to whether and why they 
have or have not been incorporated into the next itera-
tion. This will allow tracking of the evolution of the stan-
dards and indicators from the original recommendations 
on which they were based to their final iteration, as well 
as the nature and influence of review feedback in shaping 
the standard. Once the indicators are ‘stable’ with no 
further significant changes being suggested, that version 
of the standard will be published as comprising a set of 
clinical indicators that represents 'appropriate care' for 
Australians with the candidate conditions at that time. 
Endorsement will then be sought by relevant profes-
sional bodies and consumer organisations. For each 
medical condition that has undergone indicator devel-
opment via the STANDING Collaboration process, it will 
be possible for evidence to be monitored by the Curator 
Group (or a subgroup comprised of key members of the 
Curator Group) in order to update standards and indi-
cators as necessary. For each condition, our initial moni-
toring plan involves using information from automated 
database searches and feedback from the wiki to initially 
update indicators every three months and, once stable, at 
a minimum of every six months.
PhAsE 3
A multimethods evaluation of the process and products 
of phases 1 and 2 of our research methodology will be 
undertaken (table 4). Three data sources will be used to 
inform the evaluation: (A) engagement and utilisation 
statistics sourced from the wiki logs—these will include 
demographics of users and rates, times and nature of 
use; (B) the nature and content of Wiki Registrant, 
Curator Group and Clinical Champion comments (eg, 
the format and rationale of proposed changes to indica-
tors, level of agreement between reviewers and resulting 
changes to the indicators); and (C) all users and stake-
holders’ perspectives on the process, usability and appro-
priateness of the vehicle for developing the standards (ie, 
the wiki) as well as the acceptance and utility of the final 
sets of standards and indicators themselves.
Participants will be invited to provide feedback regarding 
their experiences and perspectives via one of three data 
collection methods: (1) online user perspectives survey 
(for external reviewers); (2) semistructured interviews 
(for Review Panel members and the Clinical Champion); 
and (3) interviews and focus groups (for phase 1 stake-
holders, following publication of the sets of indicators) 
(table 4). Both quantitative and qualitative analyses of 
these three data sources will be undertaken including: 
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Table 4 Description of the phase 3 evaluation of phase 1 and phase 2
Phase 3: Evaluation of processes, 
products and feasibility
Phase 1: Stakeholder 
analyses
Phase 2: Development of clinical indicators representative of 
‘appropriate care’ for a range of common conditions
Aim and purpose of evaluation Participants’ 
perceptions and 
experiences of the 
engagement process
Participants’ engagement with, and utilisation of, clinical indicator 
development process
Participants’ perspectives on the process, usability and 
appropriateness of the clinical indicator development approach 
used, and the final sets of standards and indicators
Participants Phase 1: stakeholders Phase 2: internal reviewers
(Research Team, Clinical Champions, Curator Group members)
Phase 2: external reviewers
(Wiki Registrants)
Methods Qualitative interviews Database (wiki) usage and content analyses
Qualitative focus groups (internal reviewers)
Online survey (external reviewers)
Data sources Interview data Wiki logs
Interview and survey data
Analysis Content analysis
Inductive reasoning
Descriptive statistics (wiki logs, online survey) and content 
analyses (wiki, interview and survey data)
descriptive statistics for the characteristics of wiki users, 
their engagement and patterns of use, frequency counts 
and content analyses of ratings and free-text responses 
from the online user perspectives survey, semistructured 
interviews and focus groups (table 4). Using these data, 
recommendations will be developed regarding the overall 
feasibility of the wiki process for future indicator devel-
opment. The next phase of the research is to study the 
implementation of the standards as a translational tool 
for clinical practice and ongoing audit.
EthIcs And dIssEMInAtIon
Ethical approval
Human Research Ethics Committee approval has been 
granted from the University of South Australia (protocol 
number 0000035183). All STANDING Collaboration partic-
ipants and reviewers will be required to give informed 
consent (for their chosen study phase(s)) and complete 
a COI declaration prior to participation, which will be 
recorded and managed according to an established 
protocol (appendix c, online supplementary file 3).43–46
dissemination
We will submit the results of the study to relevant 
national and international journals with the intention 
of publishing the results widely. As well, we will make 
national and international presentations to stakeholder 
groups including those involving patients, researchers, 
clinicians, managers and policymakers.
dIscussIon
Notwithstanding the large number of CPGs currently avail-
able, delivery of ‘appropriate’ healthcare in Australia and 
internationally is highly variable and leaves considerable 
room for improvement. A number of major difficulties 
have been identified with current CPGs and their devel-
opment. Our alternative approach for keeping evidence 
accessible and up to date has been designed to mitigate 
problems with existing processes. Here, we describe a 
protocol for developing and testing a process for creating 
clinical standards, embodied in clinical indicators.
This process has been designed to systematically address 
many of the problems identified with current CPGs and 
their development. The approach is characterised by 
being inclusive (HCPs, researchers and consumers), 
transparent (all reviewers’ suggestions are logged, with 
their provenance, as accepted or rejected by the Clinical 
Champion and Curator Group), up to date (revisions 
will be ongoing after a version is published), easy to use 
(one concept per indicator), written in plain English and 
able to be integrated into the sequence of work flow in 
managing a condition.2 29 30
Findings from this study will be used to inform the 
design of future studies using Delphi processes to estab-
lish consensus on recommended healthcare, and will 
be relevant for national and international researchers, 
policymakers, healthcare practitioners and patients. 
Specifically, there is potential for standards and indi-
cators developed using this methodology to be assem-
bled to comprise the content of electronic tools for the 
basic care of common conditions (ie, reflects ‘essential’ 
Australian clinical practice; appendix B, online supple-
mentary file 2). It is envisaged that the clinical tool 
(box 1) will2:
1. implicitly or explicitly enunciate the clinical standard 
for the basic care of the condition in question
2. inform HCPs, patients and carers about that condi-
tion
3. guide care
4. document what care has been offered and what has 
not (and why)
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5. be amenable to audit (preferably automated) so 
that feedback can be provided—at clinical indicator, 
patient, provider, facility and eventually population 
levels.
We recognise several limitations to our study. The 
inclusion of only English language CPGs, for pragmatic 
purposes and contextual consistency, may not be repre-
sentative of all available evidence and limits the gener-
alisability of our findings. Reviewers will be invited to 
participate and self-nominate for conditions that are 
within their scope of practice, interest or experience (ie, 
healthcare providers and consumers) which introduces a 
selection bias. Clinical indicators will be developed from 
recommendations in existing CPGs, which means there 
is potential for problems with current CPG development 
processes to contaminate our final sets of indicators and 
standards. The aim of this study is to provide proof of 
concept and test a new methodology. Our intention is that 
the key approaches and characteristics of the STANDING 
Collaboration clinical standard and indicator develop-
ment process (ie, governance structure, transparency, 
HCP and consumer engagement and codesign, access to 
provenance of both accepted and rejected suggestions, 
and use of online technologies to facilitate keeping the 
indicators up to date) will be universally applicable, and 
be able to be tailored to other healthcare settings and 
structures.30 47 48 We aim to ameliorate these limitations 
by adopting a collaborative user-centred approach where 
feedback from both consumer and HCP groups is sought, 
communicated transparently and incorporated into guid-
ance for others who wish to develop clinical standards 
and indicators.6
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